InsidersTradesSigma
Edwards Lifesciences Corp Stock: price and directors' dealings · United States · SEC (Form 4)
Track the Edwards Lifesciences Corp share price and the full insider trade history of the company, a publicly traded company based in United States. Shares are listed on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Edwards Lifesciences Corp has logged 555 public disclosures. Market capitalisation: €54.3bn. The latest transaction was filed on 7 July 2026 (Retenue fiscale). Among the most active insiders: BOBO DONALD E JR. The full history is openly available.
555
Insider Decl.
0
Thresholds
€299,415
2 ops.
Buy Volume
€10m
36 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Edwards Lifesciences Corp Buy (bullish), based on 26 analysts. Average price target: US$97.31.
44Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 10,134 of 25,484 companies
57.2
score / 100
Value35
Quality80
FCF yld2.5%
Earn yld2.0%
EV/EBITDA38.0x
ROE10%
Gross mgn78%
Net mgn18%
Debt/EBITDA0.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 7 July 2026
Declarations555 total
377 shares@ US$95.18Common StockSEC:0001225208-26-006535:0
619 sharesCommon StockSEC:0001225208-26-006263:0
619 sharesCommon StockSEC:0001225208-26-006263:1
567.527 shares@ US$86.080.0001% mcap37.3% of flowCommon StockSEC:0001225208-26-005647:0
23,145 shares@ US$86.42010.0035% mcap9.0% of flowCommon StockSEC:0001225208-26-005610:0
1,500 shares@ US$84.60350.0002% mcap1.8% of flowCommon StockSEC:0001225208-26-005576:0
47,207 shares0Common StockSEC:0001225208-26-005172:0
13,457 shares0Common StockSEC:0001225208-26-005171
47,207 shares0Common StockSEC:0001225208-26-005172
13,457 shares0Common StockSEC:0001225208-26-005171:0
19,830 shares0Common StockSEC:0001225208-26-005133
19,830 shares0Common StockSEC:0001225208-26-005133:0
3,985 shares0Common StockSEC:0001225208-26-005044:0
3,985 shares0Common StockSEC:0001225208-26-005044
515 shares@ US$83.980.0001% mcap1.9% of flowCommon StockSEC:0001225208-26-004968:0
515 shares@ US$83.980.0001% mcap1.9% of flowCommon StockSEC:0001225208-26-004968
1,019 shares@ US$59.25670.0001% mcap16.8% of flowCommon StockSEC:0001225208-26-004422:0
1,019 shares@ US$59.25670.0001% mcap16.8% of flowCommon StockSEC:0001225208-26-004422
176 shares@ US$79.780.0000% mcap20.4% of flowCommon StockSEC:0001225208-26-002408:0
176 shares@ US$79.7820.4% of flowCommon StockSEC:0001225208-26-002408
1,019 shares@ US$59.256716.6% of flowCommon StockSEC:0001225208-26-000558
1,019 shares@ US$59.25670.0001% mcap16.6% of flowCommon StockSEC:0001225208-26-000558:0
11,340 shares@ US$59.25677.9% of flowCommon StockSEC:0001225208-26-000378
11,340 shares@ US$59.25670.0012% mcap7.9% of flowCommon StockSEC:0001225208-26-000378:0
1,019 shares@ US$59.256716.5% of flowCommon StockSEC:0001225208-25-009934
25 of 555 declarations
About Edwards Lifesciences Corp
Edwards Lifesciences Corp. (ticker: EW) is a leading U.S. medical technology company listed on the NYSE in the United States. For French-speaking investors, it stands out as a highly focused cardiovascular medtech platform, with a business model centered primarily on structural heart disease. The company’s roots date back to 1958, when Miles “Lowell” Edwards set out to develop the first artificial heart. The modern company emerged from Edwards Laboratories and later became an independent public company in 2000 following its spin-off from Baxter International. Edwards is headquartered in Irvine, California, which remains an important part of its innovation and engineering identity. The company’s core business is organized around three major pillars. The first is transcatheter aortic valve replacement, or TAVR/TAVI, anchored by the SAPIEN franchise, which has become one of the most established names in aortic valve therapy worldwide. The second is transcatheter mitral and tricuspid therapies, or TMTT, a younger but strategically critical growth area as Edwards extends its reach beyond the aortic valve into more complex structural heart procedures. The third pillar is surgical structural heart, which includes tissue heart valves and related products used in complex cardiac surgery. This concentrated portfolio gives Edwards a strong clinical identity and positions the company as a specialized innovator rather than a broad-based medtech conglomerate. From a competitive standpoint, Edwards is widely regarded as a global leader in several structural heart categories, but it operates in a field with serious rivals, including Medtronic and Abbott. Its moat is based on clinical evidence, physician relationships, product innovation, and the breadth of its valve technology platform. The company distributes its products internationally and serves clinicians in nearly 100 countries, giving it meaningful geographic diversification even though the United States remains a key revenue and development market. Recent news has reinforced the investment case. In late 2025, Edwards received FDA approval for SAPIEN M3, which it described as the first transseptal transcatheter therapy approved in the U.S. for mitral regurgitation. In early 2026, management reported strong full-year 2025 results, highlighted double-digit sales growth, and increased confidence in the 2026 outlook. The company has also been active on capital allocation, including share repurchases, and announced a CFO appointment in May 2026. Overall, EW is best viewed as a premium U.S. healthcare growth stock on the NYSE, supported by a deep structural heart franchise, a strong innovation pipeline, and continued expansion into adjacent valve therapies.
